Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment.

IF 10.3 1区医学 Q1 IMMUNOLOGY

Journal for Immunotherapy of Cancer Pub Date : 2024-11-24 DOI:10.1136/jitc-2024-010074

Qiyan Cai, Yi Que, Xing Zhang

引用次数: 0

Abstract

Soft tissue sarcoma is characterized by its rarity and complexity, making it more difficult to conduct large clinical trials compared with other solid tumors. Also known as 'cold tumors,' sarcomas, especially advanced sarcomas, have poor responses to immunotherapy. Based on that, the results of two groundbreaking phase 2 clinical trials about neoadjuvant immunotherapy in patients with liposarcoma or undifferentiated pleomorphic sarcoma are encouraging. In this paper, we discuss the results of these clinical trials and the challenges we are facing to conduct neoadjuvant immunotherapy in sarcomas and call for further research to promote the development of it.

查看原文本刊更多论文

新辅助免疫疗法在不断发展的肉瘤治疗中的应用。

软组织肉瘤的特点是罕见和复杂，因此与其他实体瘤相比，开展大型临床试验更为困难。肉瘤也被称为 "冷肿瘤"，尤其是晚期肉瘤对免疫疗法的反应较差。基于此，两项关于脂肪肉瘤或未分化多形性肉瘤患者新辅助免疫疗法的突破性二期临床试验结果令人鼓舞。在本文中，我们将讨论这些临床试验的结果以及在肉瘤中开展新辅助免疫疗法所面临的挑战，并呼吁进一步开展研究以促进其发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal for Immunotherapy of Cancer Biochemistry, Genetics and Molecular Biology-Molecular Medicine

CiteScore

17.70

自引率

4.60%

发文量

522

审稿时长

18 weeks

期刊介绍： The Journal for ImmunoTherapy of Cancer (JITC) is a peer-reviewed publication that promotes scientific exchange and deepens knowledge in the constantly evolving fields of tumor immunology and cancer immunotherapy. With an open access format, JITC encourages widespread access to its findings. The journal covers a wide range of topics, spanning from basic science to translational and clinical research. Key areas of interest include tumor-host interactions, the intricate tumor microenvironment, animal models, the identification of predictive and prognostic immune biomarkers, groundbreaking pharmaceutical and cellular therapies, innovative vaccines, combination immune-based treatments, and the study of immune-related toxicity.